We have summarized the latest findings on markers for progression of immunoglobulin A (IgA) nephropathy (IgAN), the most common primary glomerulonephritis with a high prevalence among end-stage renal disease (ESRD) patients. The clinical predictors of renal outcome in IgAN nephropathy, such as proteinuria, hypertension, and decreased estimated glomerular filtration rate (eGFR) at the time of the diagnosis, are well known. The Oxford classification of IgAN identified four types of histological lesions (known as the MEST score) associated with the development of ESRD and/or a 50 % reduction in eGFR. In addition, the role of genetic risk factors associated with IgAN is being elucidated by genome-wide association studies, with multiple risk alleles described. Recently, biomarkers in serum (galactose-deficient IgA1, IgA/IgG autoantibodies against galactose-deficient IgA1, and soluble CD 89-IgA complexes) and urine (soluble transferrin receptor, interleukin-6/epidermal growth factor ratio, fractalkine, laminin G-like 3 peptide, κ light chains, and mannan-binding lectin) have been identified. Some of these biomarkers may represent candidates for the development of noninvasive diagnostic tests, that would be useful for detection of subclinical disease activity, monitoring disease progression, assessment of treatment, and at the same time circumventing the complications associated with renal biopsies. These advances, along with future disease-specific therapy, will be helpful in improving the treatment effectiveness, prognosis, and the quality of life in connection with IgAN.

Department of Nephrology 1st Faculty of Medicine Charles University Prague and General University Hospital Prague Prague 2 Czech Republic

Department of Nephrology Changhai Hospital 2nd Military Medical University 168 Changhai Road Shanghai China

Departments of Microbiology and Medicine University of Alabama at Birmingham Birmingham AL 35294 USA

Zobrazit více v PubMed

Moriyama T, Tanaka K, Iwasaki C, et al. Prognosis in IgA nephropathy: 30-year analysis of 1,012 patients at a single center in Japan. PLoS One. 2014;9:e91756. PubMed PMC

Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402–2414. PubMed

Cattran DC, Coppo R, Cook HT, et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76:534–545. PubMed

Coppo R, Troyanov S, Camilla R, et al. Working Group of the International IgA Nephropathy Network and the Renal Pathology Society, The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults. Kidney Int. 2010;77:921–927. PubMed

Feehally J, Floege J. IgA nephropathy and Henoch-Schönlein nephritis. In: Feehally J, Floege J, Johnson RJ, editors. Comprehensive clinical nephrology. 3. Mosby; 2007. pp. 253–264.

Kiryluk K, Li Y, Sanna-Cherchi S, et al. Geographic differences in genetic susceptibility to IgA nephropathy: GWAS replication study and geospatial risk analysis. PLoS Genet. 2012;8:e1002765. PubMed PMC

Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46:1187–1196. PubMed PMC

Tomana M, Matousovic K, Julian BA, et al. Galactose-deficient IgA1 in sera of IgA nephropathy patients is present in complexes with IgG. Kidney Int. 1997;52:509–516. PubMed

Tomana M, Novak J, Julian BA, et al. Circulating immune complexes in IgA nephropathy consist of IgA1 with galactose-deficient hinge region and antiglycan antibodies. J Clin Invest. 1999;104:73–81. PubMed PMC

Novak J, Raskova Kafkova L, Suzuki H, et al. IgA1 immune complexes from pediatric patients with IgA nephropathy activate cultured human mesangial cells. Nephrol Dial Transplant. 2011;26:3451–3457. PubMed PMC

Maillard N, Wyatt RJ, Julian BA, et al. Current understanding of the role of complement in IgA nephropathy. J Am Soc Nephrol. 2015;26:1503–1512. PubMed PMC

Schmitt R, Stahl AL, Olin Al, et al. The combined role of galactose-deficient IgA1 and streptococcal IgA-binding M protein in inducing IL-6 and C3 secretion from human mesangial cells: implications for IgA nephropathy. J Immunol. 2014;193:317–326. PubMed PMC

Daha MR, van Kooten C. Role of complement in IgA nephropathy. J Nephrol. 2016;29:1–4. PubMed PMC

Suzuki H, Ohsawa I, Kodama F, et al. Fluctuation of serum C3 levels reflects disease activity and metabolic background in patients with IgAnephropathy. J Nephrol. 2013;26:708–15. PubMed

Lai KN, Leung JC, Chan LY, et al. Activation of podocytes by mesangial-derived TNF-alpha: glomerulo-podocytic communication in IgA nephropathy. Am J Physiol Renal Physiol. 2008;294:F945–955. PubMed

Maixnerova D, Bauerova L, Skibova J, et al. The retrospective analysis of 343 Czech patients with IgA nephropathy–one centre experience. Nephrol Dial Transplant. 2012;27:1492–1498. PubMed

Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgA nephropathy. J Am Soc Nephrol. 2007;18:3177–3183. PubMed

Alamartine E, Sauron C, Laurent B, et al. The use of Oxford classification of IgA nephropathy to predict renal survival. Clin J Am Soc Nephrol. 2011;6:2384–2388. PubMed PMC

Berthoux F, Mohey H, Laurent B, et al. Predicting the risk for dialysis or death in IgA nephropathy. J Am Soc Nephrol. 2011;22:752–61. PubMed PMC

Barbour SJ, Cattran DC, Espino-Hernandez G, et al. Identifying the ideal metric of proteinuria as a predictor of renal outcome in idiopathic glomerulonephritis. Kidney Int. 2015;88:1392–1401. PubMed

Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis. 2012;59:865–73. PubMed

Coppo R, D’Amico G. Factors predicting progression of IgA nephropathies. J Nephrol. 2005;18:503–512. PubMed

Kaartinen K, Syrjanen J, Porsti I, et al. Inflammatory markers and the progression of IgA glomerulonephritis. Nephrol Dial Transplant. 2008;23:1285–1290. PubMed

Roberts IS, Cook HT, et al. The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility. Kidney Int. 2009;76:546–556. PubMed

Barbour SJ, Espino-Hernandez G, Reich HN, et al. Oxford Derivation, North American Validation and VALIGA Consortia. The MEST score provides earlier risk prediction in IgA nephropathy. Kidney Int. 2016;89:1671–75. PubMed

Coppo R, Troyanov S, Bellur S, et al. Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments. Kidney Int. 2014;86:828–836. PubMed PMC

Bellur SS, Troyanov S, Cook HT, et al. Immunostaining findings in IgA nephropathy: correlation with histology and clinical outcome in the Oxford classification patient cohort. Nephrol Dial Transplant. 2011;26:2533–2536. PubMed

Wada Y, Ogata H, Takeshige Y, et al. Clinical significance of IgG deposition in the glomerular mesangial area in patients with IgA nephropathy. Clin Exp Nephrol. 2013;17:73–82. PubMed PMC

Xu PC, Wei L, Shang WY, et al. Urinary kidney injury molecule-1 is related to pathologic involvement in IgA nephropathy with normotension, normal renal function and mild proteinuria. BMC Nephrol. 2014;7:107. PubMed PMC

Yanagawa H, Suzuki H, Suzuki Y, et al. A panel of serum biomarkers differentiates IgA nephropathy from other renal diseases. PLoS One. 2014;9:e98081. PubMed PMC

Nakata J, Suzuki Y, Suzuki H, et al. Changes in nephritogenic serum galactose-deficient IgA1 in IgA nephropathy following tonsillectomy and steroid therapy. PLoS One. 2014;9:e89707. PubMed PMC

Suzuki H, Raska M, Yamada K, et al. Cytokines alter IgA1 O-glycosylation by dysregulating C1GalT1 and ST6GalNAc-II enzymes. J Biol Chem. 2014;289:5330–5339. PubMed PMC

Moldoveanu Z, Wyatt RJ, Lee J, et al. Patients with IgA nephropathy have increased serum galactose-deficient IgA1 levels. Kidney Int. 2007;71:1148–1154. PubMed

Hastings MC, Moldoveanu Z, Julian BA, et al. Galactose-deficient IgA1 in African Americans with IgA nephropathy: serum levels and heritability. Clin J Am Soc Nephrol. 2010;5:2069–2074. PubMed PMC

Zhao N, Hou P, Lv J, et al. The level of galactose-deficient IgA1 in the sera of patients with IgA nephropathy is associated with disease progression. Kidney Int. 2012;82:790–796. PubMed PMC

Launay P, Grossetête B, Arcos-Fajardo M, et al. Fcα receptor (CD89) mediates the development of immunoglobulin A (IgA) nephropathy (Berger’s disease). Evidence for pathogenic soluble receptor-IgA complexes in patients and CD89 transgenic mice. J Exp Med. 2000;191:1999–2009. PubMed PMC

Berthelot L, Papista C, Maciel TT, et al. Transglutaminase is essential for IgA nephropathy development acting through IgA receptors. J Exp Med. 2012;209:793–806. PubMed PMC

Vuong MT, Hahn-Zoric M, Lundberg S, et al. Association of soluble CD89 levels with disease progression but not susceptibility in IgA nephropathy. Kidney Int. 2010;78:1281–1287. PubMed

Lechner SM, Papista C, Chemouny JM, et al. Role of IgA receptors in the pathogenesis of IgA nephropathy. J Nephrol. 2016;29:5–11. PubMed

Delanghe SE, Speeckaert MM, Segers H, et al. Soluble transferrin receptor in urine, a new biomarker for IgA nephropathy and Henoch-Schönlein purpura nephritis. Clin Biochem. 2013;46:591–597. PubMed

Peters HP, Waanders F, Meijer E, et al. High urinary excretion of kidney injury molecule-1 is an independent predictor of end-stage renal disease in patients with IgA nephropathy. Nephrol Dial Transplant. 2011;26:3581–3588. PubMed

Peters HP, van den Brand JA, Wetzels JF. Urinary excretion of low-molecular-weight proteins as prognostic markers in IgA nephropathy. Neth J Med. 2009;67:54–61. PubMed

Yasutake J, Suzuki Y, Suzuki H, et al. Novel lectin-independent approach to detect galactose-deficient IgA1 in IgA nephropathy. Nephrol Dial Transplant. 2015;30:1315–1321. PubMed PMC

Berthoux F, Suzuki H, Thibaudin L, et al. Autoantibodies targeting galactose-deficient IgA1 associate with progression of IgA nephropathy. J Am Soc Nephrol. 2012;23:1579–1587. PubMed PMC

Hastings MC, Moldoveanu Z, Suzuki H, et al. Biomarkers in IgA nephropathy: relationship to pathogenetic hits. Expert Opin Med Diagn. 2013;7:615–27. PubMed PMC

Caliskan Y, Kiryluk K. Novel biomarkers in glomerular disease. Adv Chronic Kidney Dis. 2014;21:205–216. PubMed PMC

Szeto CC, Li PK. Micro RNAs in IgA nephropathy. Nat Rev Nephrol. 2014;10:249–256. PubMed

Serino G, Sallustio F, Cox SN, et al. Abnormal miR-148b expression promotes aberrant glycosylation of IgA1 in IgA nephropathy. J Am Soc Nephrol. 2012;23:814–824. PubMed PMC

Wang N, Bu R, Duan Z, et al. Profiling and initial validation of urinary microRNAs as biomarkers in IgA nephropathy. PeerJ. 2015;3:e990. doi: 10.7717/peerj.990. PubMed DOI PMC

Li-Na Xing, Wang H, Yin PH, et al. Reduced mir-29b-3p expression up-regulate CDK6 and contributes to IgA nephropathy. Int J Clin Exp Med. 2014;7:5275–5281. PubMed PMC

Bao H, Chen H, Zhu X, et al. MiR 223 downregulation promotes glomerular endothelial cell activation by upregulating importin α4 and α5 in IgA nephropathy. Kidney Int. 2014;85:624–635. PubMed

Berthelot L, Robert T, Vuiblet V, et al. Recurrent IgA nephropathy is predicted by altered glycosylated IgA, autoantibodies and soluble CD89 complexes. Kidney Int. 2015;88:815–822. PubMed

Ranieri E, Gesualdo L, Petrarulo F, et al. Urinary IL-6/EGF ratio: a useful prognostic marker for the progression of renal damage in IgA nephropathy. Kidney Int. 1996;50:1990–2001. PubMed

Torres DD, Rossini M, Manno C, et al. The ratio of epidermal growth factor to monocyte chemotactic peptide-1 in the urine predicts renal prognosis in IgA nephropathy. Kidney Int. 2008;73:327–333. PubMed

Aizawa T, Imaizumi T, Tsuruga K, et al. Urinary fractalkine and monocyte chemoattractant protein-1 as possible predictors of disease activity of childhood glomerulonephritis. Tohoku J Exp Med. 2013;231:265–270. PubMed

Rocchetti MT, Papale M, d’Apollo AM, et al. Association of urinary laminin G-like 3 and free kappa light chains with disease activity and histological injury in IgA nephropathy. Clin J Am Soc Nephrol. 2013;8:1115–1125. PubMed PMC

Wu J, Wang N, Wang J, et al. Identification of a uromodulin fragment for diagnosis of IgA nephropathy. Rapid Commun Mass Spectrom. 2010;24:1971–1978. PubMed

Candiano G, Musante L, Bruschi M, et al. Repetitive fragmentation products of albumin and alpha1-antitrypsin in glomerular diseases associated with nephrotic syndrome. J Am Soc Nephrol. 2006;17:3139–3148. PubMed

Asao R, Asanuma K, Kodama F, et al. Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy. Clin J Am Soc Nephrol. 2012;7:1385–1393. PubMed PMC

Good DM, Zürbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics. 2010;9:2424–2437. PubMed PMC

Liu LL, Jiang Y, Wang LN, et al. Urinary mannose-binding lectin is a biomarker for predicting the progression of immunoglobulin (Ig) A nephropathy. Clin Exp Immunol. 2012;169:148–155. PubMed PMC

Sogabe A, Uto H, Kanmura S, et al. Correlation of serum levels of complement C4a desArg with pathologically estimated severity of glomerular lesions and mesangial hypercellularity scores in patients with IgA nephropathy. Int J Mol Med. 2013;32:307–314. PubMed

Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet. 2011;43:321–327. PubMed PMC

Kiryluk K, Li Y, Scolari F, et al. Discovery of new risk loci for IgA nephropathy implicates genes involved in immunity against intestinal pathogens. Nat Genet. 2014;46(11):1187–96. PubMed PMC

Li M, Foo JN, Wang JQ, et al. Identification of new susceptibility loci for IgA nephropathy in Han Chinese. Nat Commun. 2015;6:7270. doi: 10.1038/ncomms8270. PubMed DOI PMC

Suzuki H, Kiryluk K, Novak J, et al. The pathophysiology of IgA nephropathy. J Am Soc Nephrol. 2011;22:1795–1803. PubMed PMC

Toward Noninvasive Diagnosis of IgA Nephropathy: A Pilot Urinary Metabolomic and Proteomic Study